Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avoplacel - Pluri

Next Previous
Drug Profile

Avoplacel - Pluri

Alternative Names: Placenta-derived cell therapy - Pluri; PLX-R-18; PLX-RAD

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluri; United States Department of Defense
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Aplastic anaemia; Preeclampsia; IgA nephropathy; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute radiation syndrome
  • Phase I Graft-versus-host disease
  • No development reported Aplastic anaemia; Chemical burns

Most Recent Events

  • 08 Apr 2024 Pluri has patent protection for System and Methods for Immune Cells Expansion and Activation in Large Scale in the US
  • 11 Jul 2023 Pharmacodynamics data from a phase II trial in Acute radiation syndrome released by Pluri
  • 06 Jan 2023 Avoplacel is still in phase-I development in Graft-versus-host-disease (In the elderly, In adults) in Israel (IM, Injection) (Pluristem Therapeutics pipeline, January 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top